Hernández-Valencia M, Carrillo-Pacheco A, Hernández-Quijano T, Záratea A

Language: Spanish
References: 20
Page: 420-423
PDF size: 47.03 Kb.

ABSTRACT

Human papilloma virus can infect any mucous of the body and to cause cancer of the uterine cervix. The last recommendation suggests making the Papanicolaou combined with a test for detection of human papillomavirus with a frequency interval of 3 years, since it grants greater information and fi delity of the result. The detection studies should begin at the age of 21 years and should stop the pursuit at 65 years age. Until recently specifi c treatments did not exist on this burden, but have arisen some drugs that have demonstrated good effectiveness to cure the infection for human papilloma virus, as the glycirrhicinic acid that has demonstrated less adverse effects, as well as the possibility of its systemic employment, that allows to arrive to the lesions with diffi cult to approach. The medical recommendations should be in constant revision, since the trial of the clinical can modify the interpretation, for what it is necessary to personalize each patient treatment.

REFERENCES

1. Wright TC jr, Massad LS, Dunton CJ, et al. 2006 consensus guidelines for the management of women with cervical intraepithelial neoplasia or adenocarcinoma in situ. Am J Obstet Gynecol. 2007;197 (4):340-4.

2. ACOG Committee on Practice Bulletins--Gynecology. ACOG Practice Bulletin no. 109: Cervical cytology screening. Obstet Gynecol. 2009;114(6):1409-20.

3. Vesco KK, Whitlock EP, Eder M, et al. Risk factors and other epidemiologic considerations for cervical cancer screening: a narrative review for the U. S. Preventive Services Task Force. Ann Intern Med. 2011;155(10):698-705. Texto libre en http://annals. org/article.aspx?articleid=1033159

4. Datta SD, Koutsky LA, Ratelle S, et al. Human papillomavirus infection and cervical cytology in women screened for cervical cancer in the United States, 2003-2005. Ann Intern Med. 2008;148(7):493- 500. Texto libre en http://annals.org/article.aspx? articleid=740216

5. Castle PE, Fetterman B, Poitras N, et al. Five-year experience of human papillomavirus DNA and Papanicolaou test cotesting. Obstet Gynecol. 2009; 113(3):595-600. Texto libre en http://www.ncbi.nlm. nih.gov/pmc/articles/PMC2747731/

6. Cárdenas-Turanzas M, Nogueras-González GM, Scheurer ME, et al. The performance of human papillomavirus high-risk DNA testing in the screening and diagnostic settings. Cancer Epidemiol Biomarkers Prev. 2008;17(10):2865-71. Texto libre en http:// www.ncbi.nlm.nih.gov/pmc/articles/PMC2705895/

7. Petry KU, Menton S, Menton M, et al. Inclusion of HPV testing in routine cervical cancer screening for women above 29 years in Germany: results for 8466 patients. Br J Cancer. 2003;88(10)1570-7. Texto libe en http://www.ncbi.nlm.nih.gov/pmc/articles/ PMC2377109/

8. Sasieni P, Castanon A. Call and recall cervical screening programme: screening interval and age limits. Curr Diagn Pathol. 2006;12(2):114-126.

9. Sargent A, Bailey A, Almonte M, et al; ARTISTIC Study Group. Prevalence of type-specifi c HPV infection by age and grade of cervical cytology: data from the ARTISTIC trial. Br J Cancer. 2008;98(10):1704- 9. Texto libre en http://www.ncbi.nlm.nih.gov/pmc/ articles/PMC2391119/

10. Siebers AG, Klinkhamer PJ, Grefte JM, et al. Comparison of liquid-based cytology with conventional cytology for detection of cervical cancer precursors: a randomized controlled trial. JAMA. 2009;302(16):1757-64. Texto libre en: http://jama. jamanetwork.com/article.aspx?articleid=184784

11. Coste J, Cochand-Priollet B, de Cremoux P, et al.; French Society of Clinical Cytology Study Group. Cross sectional study of conventional cervical smear, monolayer cytology, and human papillomavirus DNA testing for cervical cancer screening. BMJ. 2003;326(7392):733-8. Texto libre en http:// www.bmj.com/content/326/7392/733.1?view=long& pmid=12676841

12. Chiffman M, Castle PE. Human papillomavirus: epidemiology and public health. Arch Pathol Lab Med. 2003;127(8):930-4. Texto libre en http://www.archivesofpathology. org/doi/full/10.1043/1543-2165%28 2003%29127%3C930:HPEAPH%3E2.0.CO;2

13. Sisk E, Robertson ES. Clinical implications of human papilomavirus infection. Front Biosci. 2002;7:e77-84.

14. Hernández-Valencia M, Carrillo PA, Hernández QT, et al. Clinical response to glycyrrhizinic acid in genital infection due to human papillomavirus and lowgrade squamous intraepithelial lesion. Clin Practice. 2011;93:200-2.

15. Naucler P, Ryd W, Törnberg S, et. al. Effi cacy of HPV DNA testing with cytology triage and/or repeat HPV DNA testing in primary cervical cancer screening. J Natl Cancer Inst. 2009;101(2):88-99. Texto libre en http://jnci.oxfordjournals.org/content/101/2/88.long

16. Rijkaart DC, Berkhof J, Rozendaal L, et al. Human papillomavirus testing for the detection of highgrade cervical intraepithelial neoplasia and cancer: fi nal results of the POBASCAM randomised controlled trial. Lancet Oncol. 2012;13(1):78-88. Texto libre en http://www.thelancet.com/journals/lanonc/ article/PIIS1470-2045%2811%2970296-0/abstract

17. Amin AR, Kucuk O, Khuri FR, et al. Perspectives for cancer preventions with natural compounds. J Cin Oncol. 2009;27(16):2712-25.

18. Insinga RP, Glass AG, Rush BB. Diagnoses and outcomes in cervical cancer screening: a population-based study. Am J Obstet Gynecol. 2004;191(1):105-13.

19. Hernández QT, Illanes AB, Salas LN, et al. Evaluación del tratamiento con imiquimod en infección persistente por el virus del papiloma humano con el método de reacción en cadena de la polimerasa. Ginecol Obstet Mex. 2006;74(6):317-26.

20. Kyrgiou M, Koliopoulos G, Martin-Hirsch P, et al. Obstetric outcomes after conservative treatment for intraepithelial or early invasive cervical lesions: systematic review and meta-analysis. Lancet. 2006; 367(9509):489-98.